These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9308783)

  • 1. Role of progesterone in capillary permeability in hyperstimulated rats.
    Ujioka T; Matsuura K; Kawano T; Okamura H
    Hum Reprod; 1997 Aug; 12(8):1629-34. PubMed ID: 9308783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of ovarian kinin-kallikrein system in the pathophysiology of ovarian hyperstimulation syndrome: studies in a rat model.
    Ujioka T; Matsuura K; Tanaka N; Okamura H
    Hum Reprod; 1998 Nov; 13(11):3009-15. PubMed ID: 9853847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5.
    Kitajima Y; Endo T; Nagasawa K; Manase K; Honnma H; Baba T; Hayashi T; Chiba H; Sawada N; Saito T
    Endocrinology; 2006 Feb; 147(2):694-9. PubMed ID: 16269461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats.
    Ishikawa K; Ohba T; Tanaka N; Iqbal M; Okamura Y; Okamura H
    Endocr J; 2003 Oct; 50(5):515-25. PubMed ID: 14614207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian hyperstimulation syndrome-model rats; the manifestation and clinical implication.
    Ohba T; Ujioka T; Ishikawa K; Tanaka N; Okamura H
    Mol Cell Endocrinol; 2003 Apr; 202(1-2):47-52. PubMed ID: 12770729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo intrabursal administration of bioactive lipid sphingosine-1-phosphate enhances vascular integrity in a rat model of ovarian hyperstimulation syndrome.
    Di Pietro M; Pascuali N; Scotti L; Irusta G; Bas D; May M; Tesone M; Abramovich D; Parborell F
    Mol Hum Reprod; 2017 Jun; 23(6):417-427. PubMed ID: 28379469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
    Kosmas IP; Kitsou C; Lazaros L; Markoula S; Peschos D; Mynbaev O; Tournaye H; Prapas N; Prapas I; Zikopoulos A; Galani V; Georgiou I
    Gynecol Endocrinol; 2015; 31(9):702-7. PubMed ID: 26172931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovary mediates the effects of RU486 given during proestrus on the diestrous secretion of luteinizing hormone in the rat.
    Tébar M; Ruíz A; Bellido C; Sánchez-Criado JE
    Biol Reprod; 1996 Jun; 54(6):1266-70. PubMed ID: 8724354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.
    Rizk B; Aboulghar M; Smitz J; Ron-El R
    Hum Reprod Update; 1997; 3(3):255-66. PubMed ID: 9322101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
    Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
    Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
    Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E
    Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the impact of short- and long-term supplementation of either cabergoline or clarithromycin on resolving rat ovarian hyperstimulation syndrome (OHSS) model?
    Atilgan R; Pala Ş; Yavuzkır Ş; Başpınar M; Yılmaz M; Ilhan N
    J Obstet Gynaecol; 2019 Jul; 39(5):687-694. PubMed ID: 30892121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model.
    Cenksoy C; Cenksoy PO; Erdem O; Sancak B; Gursoy R
    Eur J Obstet Gynecol Reprod Biol; 2014 Mar; 174():86-90. PubMed ID: 24405730
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Zhang J; Huang J; He X; Li N; Miao Y; Li B; Shao X; Wang N
    Gynecol Endocrinol; 2022 Apr; 38(4):318-323. PubMed ID: 35285758
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Zhang J; Huang J; He X; Li N; Miao Y; Li B; Shao X; Wang N
    Gynecol Endocrinol; 2022 Feb; 38(2):170-175. PubMed ID: 34964405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study.
    Kitsou C; Kosmas I; Lazaros L; Tzallas C; Tinelli A; Mynbaev O; Prapas N; Prapas I; Dalkalitsis A; Georgiou I
    Gynecol Endocrinol; 2016 Nov; 32(11):886-890. PubMed ID: 27223459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome.
    Şahin N; Apaydın N; Töz E; Sivrikoz ON; Genç M; Turan GA; Cengiz H; Eskicioğlu F
    Arch Gynecol Obstet; 2016 May; 293(5):1101-6. PubMed ID: 26690356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade.
    Gómez R; Simón C; Remohí J; Pellicer A
    Endocrinology; 2002 Nov; 143(11):4339-48. PubMed ID: 12399430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
    Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L
    Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.